New insider Abg V-Siv Ix Ltd claimed ownership of 943,090 shares (SEC Form 3)

2/25/26 7:30:29 PM ET

$PMN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PMN alert in real time by email

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ABG V-SIV IX Ltd

(Last)

(First)

(Middle)

430 PARK AVENUE, 12TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/03/2026

3. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	943,090	I	See Footnote⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrants	⁽⁵⁾	⁽⁵⁾	Common Shares	700,741	$14.4	I	See Footnote⁽²⁾⁽³⁾⁽⁴⁾⁽⁶⁾

1. Name and Address of Reporting Person^*

ABG V-SIV IX Ltd

(Last)

(First)

(Middle)

430 PARK AVENUE, 12TH FLOOR

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Ally Bridge Group Global Life Science Capital Partners V, L.P.

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

P.O. BOX 309, UGLAND HOUSE,

(Street)

GRAND CAYMAN,

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ABG Global Life Science Capital Partners V GP, L.P.

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

P.O. BOX 309, UGLAND HOUSE,

(Street)

GRAND CAYMAN,

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ABG Global Life Science Capital Partners V GP Ltd

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

P.O. BOX 309, UGLAND HOUSE,

(Street)

GRAND CAYMAN,

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ABG V-SIV X Ltd

(Last)

(First)

(Middle)

C/O MAPLES CORPORATE SERVICES LIMITED

P.O. BOX 309, UGLAND HOUSE,

(Street)

GRAND CAYMAN,

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.

2. Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.

3. Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.

4. Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.

5. The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.

6. The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.

Remarks:

Following the filing of this Form 3, the Reporting Persons are expected to file Forms 4 jointly with ABG Management Ltd., Ally Bridge MedAlpha Master Fund L.P., Ally Bridge Group (NY) LLC, Fan Yu and Slanix Alex.

	ABG V-SIV IX Limited, By: Ally Bridge Group Global Life Science Capital Partners V, L.P., By: ABG Global Life Science Capital Partners V GP, L.P., By: ABG Global Life Science Capital Partners V GP Limited, By: /s/ Fan Yu	02/25/2026
	Ally Bridge Group Global Life Science Capital Partners V, L.P., By: ABG Global Life Science Capital Partners V GP, L.P., its GP, By: ABG Global Life Science Capital Partners V GP Limited, its GP, By: /s/ Fan Yu, Director	02/25/2026
	ABG Global Life Science Capital Partners V GP, L.P., By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Fan Yu, Director	02/25/2026
	ABG Global Life Science Capital Partners V GP Limited, By: /s/ Fan Yu, Director	02/25/2026
	ABG V-SIV X Limited, By: /s/ Fan Yu, Director	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $PMN alert in real time by email

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Common Shares

943,090

See Footnote⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Warrants

⁽⁵⁾

Common Shares

700,741

$14.4

See Footnote⁽²⁾⁽³⁾⁽⁴⁾⁽⁶⁾

New insider Abg V-Siv Ix Ltd claimed ownership of 943,090 shares (SEC Form 3)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PMN

New insider Abg V-Siv Ix Ltd claimed ownership of 943,090 shares (SEC Form 3)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PMN

$PMN
Press Releases

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

$PMN
Insider Purchases

Director Williams Eugene bought $48,800 worth of shares (2,000 units at $24.40), increasing direct ownership by 19% to 12,397 units (SEC Form 4)

Director Williams Eugene bought $92,420 worth of shares (4,000 units at $23.11), increasing direct ownership by 63% to 10,397 units (SEC Form 4)

Chief Development Officer Kaplan Johanne bought $25,005 worth of shares (1,629 units at $15.35), increasing direct ownership by 70% to 3,941 units (SEC Form 4)

$PMN
SEC Filings

$PMN
Insider Trading

Amendment: SEC Form SCHEDULE 13G/A filed by ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

ProMIS Neurosciences Inc. filed SEC Form 8-K: Other Events

Director Williams Eugene bought $48,800 worth of shares (2,000 units at $24.40), increasing direct ownership by 19% to 12,397 units (SEC Form 4)

Director Williams Eugene bought $92,420 worth of shares (4,000 units at $23.11), increasing direct ownership by 63% to 10,397 units (SEC Form 4)